🟢 Health ETF (ARKG) is trading 3.59% up today on TRIC-I-HF trial optimism

ARKG is trading at $48.52, up 3.59%, as positive biotech sentiment follows TRIC-I-HF trial results presented at the September 2026 ESC Congress.

• AstraZeneca and Hutchmed reported encouraging late-stage lung-cancer data on September 1, supporting biotech risk appetite.
• Healthcare positioning benefits from investor rotation away from volatile technology stocks; the broader market is only modestly higher, so the move appears healthcare- and genomics-led rather than market-wide.
• Reuters reported that investors were warming to healthcare as technology faced turbulence.